Dermira Inc (NASDAQ:DERM) has been assigned an average recommendation of “Buy” from the twelve analysts that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $18.24.
A number of analysts recently commented on DERM shares. HC Wainwright set a $31.00 price objective on Kura Oncology and gave the company a “buy” rating in a research report on Wednesday, May 8th. BidaskClub lowered Zebra Technologies from a “buy” rating to a “hold” rating in a report on Tuesday. Citigroup set a $68.00 price target on Colgate-Palmolive and gave the company a “hold” rating in a report on Tuesday, March 19th. Mizuho started coverage on Sabre in a report on Thursday, June 6th. They set a “buy” rating and a $25.00 price target for the company. Finally, Needham & Company LLC reissued a “buy” rating and set a $20.00 price target on shares of Iterum Therapeutics in a report on Monday, March 25th.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in DERM. Bank of America Corp DE boosted its stake in shares of Dermira by 469.9% in the fourth quarter. Bank of America Corp DE now owns 2,172,328 shares of the biopharmaceutical company’s stock worth $15,619,000 after acquiring an additional 1,791,178 shares during the period. Vivo Capital LLC bought a new position in shares of Dermira in the first quarter worth about $9,485,000. Rhenman & Partners Asset Management AB purchased a new stake in shares of Dermira in the first quarter worth about $6,779,000. Candriam Luxembourg S.C.A. purchased a new stake in Dermira during the first quarter valued at approximately $4,743,000. Finally, Jacobs Levy Equity Management Inc. raised its position in Dermira by 68.5% during the first quarter. Jacobs Levy Equity Management Inc. now owns 763,590 shares of the biopharmaceutical company’s stock valued at $10,347,000 after purchasing an additional 310,551 shares during the period. 93.92% of the stock is owned by hedge funds and other institutional investors.
Dermira (NASDAQ:DERM) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($1.49) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.39). The firm had revenue of $2.45 million for the quarter, compared to analysts’ expectations of $2.63 million. Dermira had a negative net margin of 510.47% and a negative return on equity of 391.86%. Equities research analysts expect that Dermira will post -5.2 EPS for the current fiscal year.
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Read More: What is the balance sheet?
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.